Comment on

• 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand.

  [No authors listed] [No authors listed] N Z Med J. 1996 Jun 28;109(1024):224-31. N Z Med J. 1996. PMID: 8769031 No abstract available.
• Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.

  Milne R, Gamble G, Whitlock G, Jackson R. Milne R, et al. N Z Med J. 2003 Nov 7;116(1185):U662. N Z Med J. 2003. PMID: 14615804
• Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factors.

  Milne R, Gamble G, Whitlock G, Jackson R. Milne R, et al. N Z Med J. 2003 Nov 7;116(1185):U663. N Z Med J. 2003. PMID: 14615805
• Secondary prevention in coronary artery disease patients in South Auckland: moving targets and the current treatment gap.

  El-Jack S, Kerr A. El-Jack S, et al. N Z Med J. 2003 Nov 7;116(1185):U664. N Z Med J. 2003. PMID: 14615806